Corticosteroid Injection in Subchondral Tibial Plateau Fracture: Not Recommended
Corticosteroid injection into a knee with a subchondral tibial plateau fracture is contraindicated and should not be performed, regardless of antiplatelet therapy status. The presence of a fracture represents an absolute contraindication to intra-articular corticosteroid injection, and the patient's dual antiplatelet regimen (aspirin 81 mg + clopidogrel 75 mg) further compounds bleeding risk.
Primary Contraindication: Fracture
Corticosteroid injections are absolutely contraindicated in the presence of any fracture, as stated in recent musculoskeletal injection guidelines 1.
Subchondral fractures of the tibial plateau carry specific risk for catastrophic complications after corticosteroid injection, including osteonecrosis of the medial tibial plateau, subchondral insufficiency fracture progression, rapid joint destruction with bone loss, and accelerated osteoarthritis 2, 3.
A documented case report describes osteonecrosis of the medial tibial plateau developing after intra-articular corticosteroid injection in an elderly patient, requiring conversion to total knee arthroplasty 3.
Osseous Injury Risk from Corticosteroids
Four main adverse joint findings have been structurally observed after intra-articular corticosteroid injections: accelerated OA progression, subchondral insufficiency fracture, complications of osteonecrosis, and rapid joint destruction including bone loss 2.
Corticosteroids have a detrimental effect on cartilage lining the joint and cause reduction of bone mineral density, making them particularly hazardous in the setting of existing osseous injury 4.
The presence of a subchondral fracture indicates compromised bone integrity that would be further weakened by corticosteroid-induced bone mineral density reduction 4.
Compounding Risk: Dual Antiplatelet Therapy
The patient's dual antiplatelet therapy (aspirin 81 mg + clopidogrel 75 mg) significantly increases bleeding risk with any invasive procedure 5.
Clopidogrel inhibits platelet aggregation for the lifetime of the platelet (7–10 days), and dual antiplatelet therapy markedly increases major bleeding risk 5.
In the CURE trial, dual antiplatelet therapy with clopidogrel plus aspirin resulted in major bleeding in 3.7% of patients versus 2.7% with aspirin alone, with bleeding primarily occurring at puncture sites 5.
While the patient is on dual antiplatelet therapy for cardiovascular protection (likely post-ACS or post-stent), this regimen should be continued indefinitely for secondary prevention 6.
Management Algorithm
Step 1: Confirm Fracture Diagnosis
- Obtain or review recent imaging (CT or MRI) to confirm the presence and extent of subchondral tibial plateau fracture 7, 8.
Step 2: Orthopedic Consultation
- Refer immediately to orthopedic surgery for fracture management, as high-energy tibial plateau fractures require specialized treatment strategies including potential staged fixation 7, 8.
- A sequential "scan-span-plan" strategy with temporary external fixation may be indicated for complex fractures 8.
Step 3: Pain Management Alternatives
- Use oral analgesics (acetaminophen, NSAIDs if not contraindicated by cardiovascular risk) rather than intra-articular injection for pain control.
- Consider physical therapy modalities and bracing once fracture stability permits.
- Avoid any intra-articular injection until fracture healing is complete and confirmed on imaging.
Step 4: Antiplatelet Management
- Continue dual antiplatelet therapy (aspirin 81 mg + clopidogrel 75 mg) without interruption unless orthopedic surgery requires temporary cessation for definitive fracture fixation 6.
- If surgery is planned, clopidogrel should be interrupted for five days prior to procedures with major bleeding risk, then restarted as soon as hemostasis is achieved 5.
Critical Pitfalls to Avoid
Never perform corticosteroid injection into a joint with known fracture, even if the fracture appears "minor" or "stable" on imaging 1.
Do not assume that ultrasound guidance makes the procedure safer in the presence of fracture—the contraindication is absolute regardless of imaging modality 4.
Do not delay orthopedic referral while attempting conservative management with injection therapy, as tibial plateau fractures often require surgical intervention and delayed treatment worsens outcomes 7, 8.
Do not discontinue dual antiplatelet therapy to facilitate injection, as the cardiovascular risk of stopping these medications far outweighs any benefit from corticosteroid injection, and the injection itself remains contraindicated due to the fracture 6.
Long-Term Considerations
Even after fracture healing, consider the patient's long-term risk profile before any future corticosteroid injections, as the literature suggests potential for accelerated osteoarthritis progression and other adverse joint events 2, 9.
If post-traumatic arthritis develops after fracture healing, alternative intra-articular therapies such as hyaluronic acid or platelet-rich plasma have more favorable safety profiles than corticosteroids 9.